<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lymphoid proliferations of the salivary glands can be either reactive or neoplastic </plain></SENT>
<SENT sid="1" pm="."><plain>Reactive lesions include cystic <z:mp ids='MP_0000688'>lymphoid hyperplasia</z:mp>--a multicystic ductal proliferation with reactive germinal centers, seen most often in intravenous drug users infected with HIV--and the lymphoepithelial <z:mp ids='MP_0001870'>sialadenitis</z:mp> of <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sj√∂gren's syndrome</z:e> (so-called benign lymphoepithelial lesion [BLEL] or myoepithelial <z:mp ids='MP_0001870'>sialadenitis</z:mp> [MESA]) </plain></SENT>
<SENT sid="2" pm="."><plain>This lymphoid proliferation involves infiltration of ductal epithelium by lymphocytes of marginal zone or monocytoid B-cell type, forming lymphoepithelial lesions (epimyoepithelial islands) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with lymphoepithelial <z:mp ids='MP_0001870'>sialadenitis</z:mp> have a 44-fold increased risk of developing salivary gland or extrasalivary <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, of which 80% are marginal zone/MALT type </plain></SENT>
<SENT sid="4" pm="."><plain>Broad strands of marginal zone or monocytoid B cells around lymphoepithelial lesions and monotypic immunoglobulin detection by immunohistochemistry are considered diagnostic of MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>B-cell clones are detected in over 50% of cases of MESA by molecular genetic methods, but this does not correlate with overlymphoma. "Nodal" type B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of the salivary glands are either follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (35%), which may arise in intrasalivary gland lymph nodes and behave similarly to follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in other sites, or diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (30%), which may arise de novo or secondary to either MALT or follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>